CN112390887B - 抗体、产生所述抗体的杂交瘤、及其用途 - Google Patents

抗体、产生所述抗体的杂交瘤、及其用途 Download PDF

Info

Publication number
CN112390887B
CN112390887B CN202011258954.4A CN202011258954A CN112390887B CN 112390887 B CN112390887 B CN 112390887B CN 202011258954 A CN202011258954 A CN 202011258954A CN 112390887 B CN112390887 B CN 112390887B
Authority
CN
China
Prior art keywords
antibody
antigen
amino acid
seq
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN202011258954.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN112390887A (zh
Inventor
游丞德
赖建勋
陈怡如
王正琪
蔡易芊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OBI Pharma Inc
Original Assignee
OBI Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OBI Pharma Inc filed Critical OBI Pharma Inc
Priority to CN202011258954.4A priority Critical patent/CN112390887B/zh
Publication of CN112390887A publication Critical patent/CN112390887A/zh
Application granted granted Critical
Publication of CN112390887B publication Critical patent/CN112390887B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
CN202011258954.4A 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途 Expired - Fee Related CN112390887B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011258954.4A CN112390887B (zh) 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461977824P 2014-04-10 2014-04-10
US61/977,824 2014-04-10
US201462057381P 2014-09-30 2014-09-30
US62/057,381 2014-09-30
PCT/US2015/025305 WO2015157629A2 (en) 2014-04-10 2015-04-10 Antibodies, pharmaceutical compositions and uses thereof
CN201580011286.6A CN106456727B (zh) 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途
CN202011258954.4A CN112390887B (zh) 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580011286.6A Division CN106456727B (zh) 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途

Publications (2)

Publication Number Publication Date
CN112390887A CN112390887A (zh) 2021-02-23
CN112390887B true CN112390887B (zh) 2023-09-26

Family

ID=54288553

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011258954.4A Expired - Fee Related CN112390887B (zh) 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途
CN201580011286.6A Expired - Fee Related CN106456727B (zh) 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580011286.6A Expired - Fee Related CN106456727B (zh) 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途

Country Status (17)

Country Link
US (2) US9902779B2 (enExample)
EP (2) EP3662928A1 (enExample)
JP (1) JP2017512759A (enExample)
KR (1) KR101966408B1 (enExample)
CN (2) CN112390887B (enExample)
AU (2) AU2015243246B2 (enExample)
BR (1) BR112016020009A2 (enExample)
CA (2) CA2941029C (enExample)
CL (1) CL2016002569A1 (enExample)
ES (1) ES2772817T3 (enExample)
IL (2) IL246837B (enExample)
PH (1) PH12016501976A1 (enExample)
RU (1) RU2016138744A (enExample)
SG (1) SG11201607258SA (enExample)
TW (3) TWI695013B (enExample)
WO (1) WO2015157629A2 (enExample)
ZA (1) ZA201605175B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3046588B1 (en) 2013-09-17 2022-03-02 OBI Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
TW201622743A (zh) 2014-03-19 2016-07-01 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 免疫原醣肽、包含該醣肽之組合物及其用途
ES2772817T3 (es) 2014-04-10 2020-07-08 Obi Pharma Inc Anticuerpos de unión a antígenos de carbohidrato asociados a tumor, composiciones farmacéuticas y sus usos
EP3344806A4 (en) 2015-09-04 2019-03-20 OBI Pharma, Inc. GLYCANARRAYS AND METHOD OF USE
AU2016335842A1 (en) 2015-10-07 2018-04-12 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
IL262296B2 (en) 2016-04-22 2024-09-01 Obi Pharma Inc Cancer immunotherapy by immune activation or immune modulation via globo series antigens
GB201612317D0 (en) * 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
KR20190067765A (ko) 2016-07-27 2019-06-17 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
WO2018094414A1 (en) * 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
US10781265B2 (en) * 2017-05-24 2020-09-22 Development Center For Biotechnology Humanized antibodies against Globo H and uses thereof in cancer treatments
KR20200131846A (ko) * 2018-03-14 2020-11-24 메모리얼 슬로안 케터링 캔서 센터 항-폴리시알산 항체 및 그 용도
CN112312924A (zh) * 2018-06-01 2021-02-02 台湾浩鼎生技股份有限公司 通过使用抗Globo H或抗SSEA-4抗体与抗负面免疫检查点抗体的联合疗法
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
AU2020245607A1 (en) * 2019-03-28 2021-12-02 Ming-Tain Lai Companion diagnostic assay for Globo-H related cancer therapy
TWI817350B (zh) * 2021-02-09 2023-10-01 台灣浩鼎生技股份有限公司 與Globo系列抗原結合之嵌合抗原受體及其用途
WO2026052782A1 (en) 2024-09-06 2026-03-12 Tacalyx Gmbh Anti-globo h antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1535282A (zh) * 2001-04-06 2004-10-06 神经节苷脂相关的重组抗体及其在肿瘤的诊断和治疗中的应用
CN1997670A (zh) * 2004-07-01 2007-07-11 诺和诺德公司 人类抗－kir抗体
CN101115773A (zh) * 2005-02-07 2008-01-30 格黎卡特生物技术股份公司 结合egfr的抗原结合分子，编码它的载体，及其应用
CN101589062A (zh) * 2006-09-20 2009-11-25 安姆根有限公司 与胰高血糖素受体抗体相关的组合物和方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
EP1266014A2 (en) 2000-03-24 2002-12-18 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
ATE346866T1 (de) * 2001-09-14 2006-12-15 Affimed Therapeutics Ag Multimerische, einzelkettige, tandem-fv- antikörper
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
EP1505075B1 (en) 2002-04-30 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Antibody to human insulin-like growth factor
CA2487932A1 (en) * 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
ES2366626T3 (es) 2004-02-06 2011-10-24 University Of Massachusetts Anticuerpos contra toxinas de clostridium difficile y usos de los mismos.
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
ZA200705695B (en) * 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
JP5238936B2 (ja) * 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
US20100145032A1 (en) * 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
MX2010013931A (es) 2008-06-16 2011-06-01 Academia Sinica Diagnosis de cancer basada en niveles de anticuerpos contra globo h y sus fragmentos.
JP2011524375A (ja) * 2008-06-16 2011-09-01 アカデミア シニカ ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用
TWI583393B (zh) * 2009-06-16 2017-05-21 中央研究院 免疫原性組合物、包含其之疫苗與治療劑及其用途
WO2011016238A1 (en) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
KR101764453B1 (ko) 2010-04-09 2017-08-02 아베오 파마슈티컬즈, 인크. 항-erbb3 항체
CA2803222A1 (en) * 2010-07-01 2012-01-05 Dsm Ip Assets B.V. A method for the production of a compound of interest
PH12013500315A1 (en) * 2010-08-16 2013-04-29 Amgen Inc Antibodies that bind myostatin, compositions and methods
WO2012088094A2 (en) * 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
EP2497782A1 (en) 2011-03-08 2012-09-12 Alzinova AB Anti oligomer antibodies and uses thereof
EP2764364B1 (en) 2011-10-06 2021-08-18 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
TW201622743A (zh) 2014-03-19 2016-07-01 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 免疫原醣肽、包含該醣肽之組合物及其用途
ES2772817T3 (es) 2014-04-10 2020-07-08 Obi Pharma Inc Anticuerpos de unión a antígenos de carbohidrato asociados a tumor, composiciones farmacéuticas y sus usos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1535282A (zh) * 2001-04-06 2004-10-06 神经节苷脂相关的重组抗体及其在肿瘤的诊断和治疗中的应用
CN1997670A (zh) * 2004-07-01 2007-07-11 诺和诺德公司 人类抗－kir抗体
CN101115773A (zh) * 2005-02-07 2008-01-30 格黎卡特生物技术股份公司 结合egfr的抗原结合分子，编码它的载体，及其应用
CN101589062A (zh) * 2006-09-20 2009-11-25 安姆根有限公司 与胰高血糖素受体抗体相关的组合物和方法

Also Published As

Publication number Publication date
AU2015243246A1 (en) 2016-09-08
EP3129048A2 (en) 2017-02-15
TWI697503B (zh) 2020-07-01
CA3104268A1 (en) 2015-10-15
TWI609886B (zh) 2018-01-01
IL246837B (en) 2020-08-31
US10815307B2 (en) 2020-10-27
SG11201607258SA (en) 2016-10-28
EP3129048A4 (en) 2017-10-25
IL246837A0 (en) 2016-08-31
CA2941029C (en) 2021-02-16
RU2016138744A (ru) 2018-05-11
TWI695013B (zh) 2020-06-01
CN112390887A (zh) 2021-02-23
EP3662928A1 (en) 2020-06-10
WO2015157629A2 (en) 2015-10-15
CL2016002569A1 (es) 2017-09-08
KR20160137984A (ko) 2016-12-02
AU2018253589A1 (en) 2018-11-22
IL276695A (en) 2020-09-30
KR101966408B1 (ko) 2019-04-05
ZA201605175B (en) 2017-09-27
AU2018253589B2 (en) 2020-04-16
WO2015157629A3 (en) 2015-12-03
BR112016020009A2 (pt) 2017-10-17
IL276695B (en) 2021-09-30
US9902779B2 (en) 2018-02-27
CN106456727B (zh) 2020-11-27
TW201738277A (zh) 2017-11-01
US20170029526A1 (en) 2017-02-02
EP3129048B1 (en) 2020-01-15
PH12016501976A1 (en) 2016-12-19
CA2941029A1 (en) 2015-10-15
JP2017512759A (ja) 2017-05-25
AU2015243246B2 (en) 2018-09-06
ES2772817T3 (es) 2020-07-08
CN106456727A (zh) 2017-02-22
TW201546092A (zh) 2015-12-16
TW201738276A (zh) 2017-11-01
RU2016138744A3 (enExample) 2018-05-11
US20180134799A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
AU2018253589B2 (en) Antibodies, pharmaceutical compositions and uses thereof
US11236154B2 (en) Carbohydrate antibodies, pharmaceutical compositions and uses thereof
TWI811604B (zh) 抗體、醫藥組成物及其用途
CN103917559B (zh) 艰难梭菌抗体
JP2010518873A (ja) アンタゴニスト抗ｏｘ４０抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用
TW201718641A (zh) 抗血管內皮生長因子受體２（ｖｅｇｆｒ２）抗體
CN117480188A (zh) 新颖糖类抗体、医药组成物及其用途
HK40037463A (en) Antibodies, hybridoma producing such antibodies and uses thereof
HK40037463B (en) Antibodies, hybridoma producing such antibodies and uses thereof
HK1232767A1 (en) Antibodies, hybridoma producing such antibodies and uses thereof
HK1232767B (en) Antibodies, hybridoma producing such antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40037463

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230926